terzepatide vs semaglutide A new headline out about the investigational drug tirzepatide was published this week. This medicine is a dual GLP-1/GIP agonist. The average weight loss on the high dose over 72 weeks was Semaglutide vs. Tirzepatide: What's the
Description
This comparison revealed a significant overlap between the upregulated genes (Fig

The side effects typically diminish as your system finds its new equilibrium
Studies in patients starting semaglutide show measurable weight loss begins within 46 weeks at therapeutic doses

Meta-analysis: do irritable bowel syndrome symptoms vary between men and women

Diabet Med 33(11):15901597

These tests can help ensure your blood is not too thick or too thin
